Details of the Drug Combination

General Information of Drug Combination (ID: DCHJ3N7)

Drug Combination Name
Alogliptin
Indication
Disease Entry Status REF
Type-2 diabetes Approved [1]

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Alogliptin
Disease Entry ICD 11 Status REF
Type-2 diabetes 5A11 Approved [2]
Alogliptin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Dipeptidyl peptidase 4 (DPP-4) TTDIGC1 DPP4_HUMAN Inhibitor [3]
------------------------------------------------------------------------------------
Alogliptin Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [4]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Metabolism [4]
------------------------------------------------------------------------------------
Alogliptin Interacts with 3 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Increases ADR [5]
Cytochrome P450 2D6 (CYP2D6) OTZJC802 CP2D6_HUMAN Increases ADR [5]
Dipeptidyl peptidase 4 (DPP4) OT16MVL9 DPP4_HUMAN Affects Binding [6]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Type 2 Diabetes Mellitus DC8SIBJ N. A. Phase 1 [7]
Diabetes Mellitus, Type 2 DCW2VQ9 N. A. Phase 1 [8]
------------------------------------------------------------------------------------

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6319).
3 Clinical pipeline report, company report or official report of Takeda (2009).
4 An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus. Clin Exp Pharmacol Physiol. 2015 Dec;42(12):1225-38.
5 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
6 Novel hydrazine derivatives as selective DPP-IV inhibitors: findings from virtual screening and validation through molecular dynamics simulations. J Mol Model. 2014 Apr;20(4):2118. doi: 10.1007/s00894-014-2118-7. Epub 2014 Apr 1.
7 ClinicalTrials.gov (NCT00856284) Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus
8 ClinicalTrials.gov (NCT01023581) Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes